Evaluation of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II assay with Korean samples
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yun, Seung Gyu | - |
dc.contributor.author | Kim, Sang-wook | - |
dc.contributor.author | Sohn, Ji Yeon | - |
dc.contributor.author | Cho, Yunjung | - |
dc.date.accessioned | 2021-09-01T12:53:48Z | - |
dc.date.available | 2021-09-01T12:53:48Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 0887-8013 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/64263 | - |
dc.description.abstract | Background The seroprevalence rate of human T-lymphotropic virus I and II (HTLV-I/II) in Korean blood donors has been known as 0.004%, and HTLV-I/II Ab screening test has been performed since 2008 in Korea. Korea Ministry of Food and Drug Safety (MFDS) approved two chemiluminescent microparticle immunoassays (CMIA) for testing HTLV-I/II antibody, ABBOTT PRISM HTLV-I/HTLV-II and ARCHITECT rHTLV-I/II. A multicenter performance evaluation study in Europe and Japan was carried out with the new electrochemiluminescence immunoassay (ECLIA) for HTLV-I/II antibody detection, Elecsys HTLV-I/II assay which launched in 2017, but not in Korea. We aimed to evaluate the clinical performance of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II for the detection of HTLV-I/II antibody with Korean samples. Methods For sensitivity evaluation, 100 HTLV-I/II-positive Korean standards from Korean Red Cross and two HTLV-II-positive samples that were purchased from Seracure were used. For the specificity, 500 potential donor specimens from Korea University Hospital healthcare center were used. All the samples were simultaneously analyzed by the two HTLV-I/II assays, Elecsys HTLV-I/II assay and ARCHITECT rHTLV-I/II assay. Results Elecsys HTLV-I/II assay and ARCHITECT rHTLV-I/II assay showed a complete agrement. Elecsys HTLV-I/II assay showed 100% sensitivity (95% CI: 96.38-100.0) and specificity (95% CI: 99.26-100.0). Conclusions Elecsys HTLV-I/II assay is as reliable as ARCHITECT rTHLV-I/II assay, and can be used as a screening test for HTLV-I/II in Korea. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | VIRUS TYPES I | - |
dc.subject | INFECTION | - |
dc.title | Evaluation of Elecsys HTLV-I/II assay in comparison with ARCHITECT rHTLV-I/II assay with Korean samples | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, Seung Gyu | - |
dc.contributor.affiliatedAuthor | Cho, Yunjung | - |
dc.identifier.doi | 10.1002/jcla.22909 | - |
dc.identifier.scopusid | 2-s2.0-85069438835 | - |
dc.identifier.wosid | 000476561200024 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL LABORATORY ANALYSIS, v.33, no.6 | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL LABORATORY ANALYSIS | - |
dc.citation.title | JOURNAL OF CLINICAL LABORATORY ANALYSIS | - |
dc.citation.volume | 33 | - |
dc.citation.number | 6 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Medical Laboratory Technology | - |
dc.relation.journalWebOfScienceCategory | Medical Laboratory Technology | - |
dc.subject.keywordPlus | VIRUS TYPES I | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordAuthor | blood donor screening | - |
dc.subject.keywordAuthor | clinical performance | - |
dc.subject.keywordAuthor | HTLV-I | - |
dc.subject.keywordAuthor | II | - |
dc.subject.keywordAuthor | Korean | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.